Log in

Relevant bibliographies by topics / Insulin / Journal articles

To see the other types of publications on this topic, follow the link: Insulin.

Journal articles on the topic 'Insulin'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Insulin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Hansenne, Isabelle Sylvie, Chantal Renard, and Vincent Geenen. "Igf2 expression is required for complete tolerance to insulin (128.19)." Journal of Immunology 178, no. 1_Supplement (2007): S213—S214. http://dx.doi.org/10.4049/jimmunol.178.supp.128.19.

Full text

Abstract:

Abstract All members of insulin gene family are transcribed in human thymus according a hierarchy whereby IGF2 expression (thymic epithelial cells/TEC) exceeds IGF1 (macrophages), which exceeds INS (medullary TEC). Type 1 and type 2 IGF receptors are expressed by thymic T-cell populations. To further study the expression of IGF-2 in thymus, the dominance of this factor was compared to insulin, while ontogenesis of Igf2, insulin1 and insulin2 transcription was studied in Balb/c pancreas and thymus. In 4-wk old thymi, IGF-2 concentration is higher than insulin content. Ontogenesis of Igf2, insul

APA, Harvard, Vancouver, ISO, and other styles

2

Shestakova, Marina Vladimirovna, and Irina Vladimirovna Glinkina. "Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506)." Diabetes mellitus 13, no. 1 (2010): 88–90. http://dx.doi.org/10.14341/2072-0351-6022.

Full text

Abstract:

Results of 31 controlled randomized studies of insulin glargine given to patients with diabetes mellitus are reviewed to evaluate the frequency of malignantneoplasms. 52 tumours were diagnosed in 45 (0.8%) patients on insulin glargine therapy and 48 tumors in 46 (0.9%) patients using other insulins(mostly NPX insulin). The incidence of breast cancer was equal (0.1%) in both groups (4 and 6 cases respectively). These data indicate thatthe use of insuline glargine does not increase the risk of malignancy, e.g. breast cancer.

APA, Harvard, Vancouver, ISO, and other styles

3

Dąbrowski, Mariusz. "U kogo i dlaczego warto zastosować insulinę dwuanalogową aspart + degludec?" Medycyna Faktów 16, no. 2(59) (2023): 227–33. http://dx.doi.org/10.24292/01.mf.0223.15.

Full text

Abstract:

Ostatnie lata przyniosły istotne zmiany paradygmatu terapii cukrzycy typu 2. Po ogłoszeniu wyników pierwszych i kolejnych badań bezpieczeństwa sercowo-naczyniowego leków przeciwcukrzycowych na pierwszą linię frontu wysunęły się leki nieinsulinowe, a szczególne miejsce zajęły inhibitory kotransportera sodowo-glukozowego typu 2 i agoniści receptora glukagonopodobnego peptydu-1 (te drugie są rekomendowane jako pierwsza terapia iniekcyjna w cukrzycy typu 2). Spowodowało to nieznaczny spadek liczby pacjentów leczonych insuliną. Niemniej należy pamiętać, że w populacji osób z cukrzycą typu 2 u wielu

APA, Harvard, Vancouver, ISO, and other styles

4

Modi, K. D., Pradeep V. Gadge, Pradeep Jain, et al. "Clinical challenges with excipients in insulin formulations and role of concentrated insulin." International Journal of Basic & Clinical Pharmacology 8, no. 4 (2019): 821. http://dx.doi.org/10.18203/2319-2003.ijbcp20191125.

Full text

Abstract:

Most of the insulin formulations in clinical use contain phenol, meta-cresol or both as excipients. These excipients in insulin preparations provide stability and have antimicrobial properties. However, they are reported to be associated with undesirable side-effects especially localised allergic reactions. Amount of excipients injected per unit dose of insulin is a major determining factor in causation of these reactions. This review discusses the excipients in different insulin formulations available in India with potential of precipitating undesirable effects and the use of concentrated ins

APA, Harvard, Vancouver, ISO, and other styles

5

Kucera, Michelle L., and John P. Graham. "Insulin Lispro, a New Insulin Analog." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 18, no. 3 (1998): 526–38. http://dx.doi.org/10.1002/j.1875-9114.1998.tb03116.x.

Full text

Abstract:

Insulin lispro is a rapid‐acting insulin analog to regular insulin. Inversion of the proline‐lysine amino acid sequence at positions 28 and 29 on the B chain is responsible for its more rapid absorption, faster onset, and shorter duration of action compared with regular insulin. The fast onset of action allows for greater flexibility in dosing and mealtime scheduling. Insulin lispro provides equivalent or slightly improved glycemic control in patients with types I and II diabetes mellitus compared with regular insulin, without subsequent increases in hypoglycemic episodes. It also results in g

APA, Harvard, Vancouver, ISO, and other styles

6

Ray, Sumit. "Insulin infusion protocol (Human insulin®/Insugen®)." Current Medicine Research and Practice 4, no. 4 (2014): 186–87. http://dx.doi.org/10.1016/j.cmrp.2014.08.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Gargiulo, P., U. Di Mario, O. Zuccarini, et al. "Treatment of diabetic pregnant women with monocomponent insulins." Acta Endocrinologica 113, no. 3_Suppl (1986): S60—S65. http://dx.doi.org/10.1530/acta.0.111s0060.

Full text

Abstract:

Abstract. Very little immunological research has been undertaken in pregnant diabetic women in relation to insulin therapy. We investigated the relations between treatment with insulins of varied immunogenic character and the presence of immune factors such as insulin antibodies, immune complexes and insulin antiinsulin complexes as well as some maternal and neonatal complications of diabetic pregnancy. 128 insulin treated diabetic pregnant women and 121 of their newborns were included in the study. The incidence of insulin antibodies, immune complexes and insulin antiinsulin complexes was low

APA, Harvard, Vancouver, ISO, and other styles

8

Mbanya, Jean Claude, Juergen Sandow, Wolfgang Landgraf, and David R. Owens. "Recombinant Human Insulin in Global Diabetes Management – Focus on Clinical Efficacy." European Endocrinology 13, no. 01 (2017): 21. http://dx.doi.org/10.17925/ee.2017.13.01.21.

Full text

Abstract:

Biosynthetic human insulin and insulin analogues are the mainstay of insulin therapy for both type 1 and type 2 diabetes although access to human insulin at affordable prices remains a global issue. The world is experiencing an exponential rise in the prevalence of diabetes presenting an urgent need to establish effective diabetes therapy in countries burdened by inadequate health care budgets, malnutrition and infectious diseases. Recombinant human insulin has replaced animal insulins and animal-based semisynthetic human insulin thereby available in sufficient quantities and at affordable pri

APA, Harvard, Vancouver, ISO, and other styles

9

Ahmed Aziz, Kamran Mahmood. "Role of New Insulin Analogs in the Management of Diabetes. A Clinical Review." Diabetes & Obesity International Journal 8, no. 1 (2023): 1–8. http://dx.doi.org/10.23880/doij-16000269.

Full text

Abstract:

This paper has reviewed different insulin analogs currently available in the market and pharma industry, their safety, efficacy and their roles in the diabetes management, comparing with human regular and NPH insulin. Traditional insulins (human regular and NPH insulins) do not have constant or smoother pharmacokinetic and pharmacodynamic profiles and are usually associated with erratic blood glucose profiles with hypoglycemia or hyperglycemia when compared with analog insulins. Similarly they do not match physiologic insulin profiles with basal bolus format. According to the medical literatur

APA, Harvard, Vancouver, ISO, and other styles

10

Hirsch, Irl B., Rattan Juneja, John M. Beals, Caryl J. Antalis, and Eugene E. Wright. "The Evolution of Insulin and How it Informs Therapy and Treatment Choices." Endocrine Reviews 41, no. 5 (2020): 733–55. http://dx.doi.org/10.1210/endrev/bnaa015.

Full text

Abstract:

Abstract Insulin has been available for the treatment of diabetes for almost a century, and the variety of insulin choices today represents many years of discovery and innovation. Insulin has gone from poorly defined extracts of animal pancreata to pure and precisely controlled formulations that can be prescribed and administered with high accuracy and predictability of action. Modifications of the insulin formulation and of the insulin molecule itself have made it possible to approximate the natural endogenous insulin response. Insulin and insulin formulations had to be designed to produce ei

APA, Harvard, Vancouver, ISO, and other styles

11

ZHANG, Zhou. "Protein engineering of insulin: Two novel fast-acting insulins [B16Ala]insulin and [B26Ala]insulin." Science in China Series C 46, no. 5 (2003): 474. http://dx.doi.org/10.1360/01yc0295.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Harned, Leighton Kahle, and Edward Chin. "PSUN278 Factitious hypoglycemia, diagnostic delay due to insulin assay failure to detect insulin analogues." Journal of the Endocrine Society 6, Supplement_1 (2022): A403. http://dx.doi.org/10.1210/jendso/bvac150.838.

Full text

Abstract:

Abstract Factitious hypoglycemia may be difficult to diagnose clinically. Hypoglycemia due to insulin self-administration is established by the presence of a low c-peptide and elevated plasma insulin levels. Commercial insulin assays often fail to detect insulin analogs and can create confusion among providers investigating causes of hypoglycemia. A 20 year old female with no significant past medical history presented to an Emergency Room (ER) with hypoglycemia. She was treated with a single dose of octreotide 150 mcg, dexamethasone 10 mg PO and started on a D10W drip at 100ml/hr prior to tran

APA, Harvard, Vancouver, ISO, and other styles

13

Dzhavakhishvili, T. S., T. I. Romantsova, and O. V. Roik. "Influence of the dynamics of body weight on the risk factors of cardiovascular disease in patients with type 2 diabetes during the first year of insulin treatment." Obesity and metabolism 10, no. 1 (2013): 22–25. http://dx.doi.org/10.14341/2071-8713-5067.

Full text

Abstract:

The aim of the present study was to investigate whether insulin treatment-induced weight gain had an adverse impact on cardiovascular risk factors in insulin-treated type 2 diabetic patients during the first year after initiating insulin therapy when insulin analogues or human insulins are used. A total of 157 patients with newly insulinized type 2 diabetes were included in the study. The patients were divided in two groups. First group consisted of subjects (mean age 57 [45; 73], duration of diabetes of 10 years [4; 16]) who had received long-acting basal (glargine, detemir), premixed (biphas

APA, Harvard, Vancouver, ISO, and other styles

14

Hale, Genevieve, Valerie Marcellus, Tina Benny, Cynthia Moreau, Elaina Rosario, and Alexandra Perez. "Real-World Analysis of Long-Acting and NPH-Containing Insulins on Glycemic Control." Senior Care Pharmacist 39, no. 1 (2024): 42–49. http://dx.doi.org/10.4140/tcp.n.2024.42.

Full text

Abstract:

Introduction Affordability of insulin products has become a concern in the past several years as the average price of various insulin products has increased. While awaiting legislation at the federal level that would address issues leading to high insulin costs, providers may have shifted prescribing practices to prescribe the lowest-priced insulin products to achieve patients’ treatment goals. Objective To compare the prevalence of hypoglycemic events between patients receiving lower-cost neutral protamine Hagedorn (NPH)-containing human insulins and higher-cost long-acting insulin analogs in

APA, Harvard, Vancouver, ISO, and other styles

15

Patel, Supriya. "Biosimilar insulins in diabetes management: A cost-effective shift in therapeutic options." Innovations in Pharmacy Planet 12, no. 01 (2024): 16–19. https://doi.org/10.31690/ipplanet.2024.v012i01.005.

Full text

Abstract:

Insulin therapy has been crucial in diabetes management since the 1920s. The emergence of biosimilar insulins, developed after the patent expiration of original insulin analogs, represents a major shift in diabetes care. These biosimilars are highly similar to their reference products in terms of safety, efficacy, and immunogenicity. Current biosimilar formulations, including insulin glargine, insulin lispro, and insulin aspart, have shown comparable clinical outcomes to their originator counterparts while offering cost-effective alternatives that improve patient access to treatment. Regulator

APA, Harvard, Vancouver, ISO, and other styles

16

Jermendy, György. "Intensive conservative insulin treatment in patients with type 2 diabetes mellitus." Orvosi Hetilap 153, no. 38 (2012): 1487–93. http://dx.doi.org/10.1556/oh.2012.29451.

Full text

Abstract:

In the last couple of years, the intensive conservative insulin treatment (basal-bolus regime) became more and more popular even in patients with type 2 diabetes. Using this insulin treatment, continuous patient education, co-operation between the medical team (diabetologist, dietician and diabetes-nurses) and the patient as well as the availability of modern insulins, pens and glucometers are of great importance. Clearly, the basal-bolus treatment with human insulin has advantages over the conservative (conventional) treatment with twice daily premix insulins. Moreover, the basal-bolus treatm

APA, Harvard, Vancouver, ISO, and other styles

17

Demidova, Tatiana Y., and Olga V. Balutina. "Special aspects of concentrated insulins: basic characteristics and research findings." Diabetes mellitus 22, no. 5 (2020): 481–90. http://dx.doi.org/10.14341/dm10334.

Full text

Abstract:

The appearance of concentrated insulins in clinical practice determines the need to analyze product priorities in appropriate groups of patients with diabetes. The aim of this article is to summarize the literature on concentrated insulins (i.e. insulin lispro 200 units/mL, insulin degludec 200 units/mL, insulin glargine 300 units/mL) from randomized controlled trials, derive guidance on appropriate and safe use of these agents and demonstrate experience in real clinical practice. Severe hypoglycemia in all studies was generally low (though higher with prandial plus concentrated basal analogue

APA, Harvard, Vancouver, ISO, and other styles

18

Broussard, John D., and Mark E. Peterson. "Comparison of two ultralente insulin preparations with protamine zinc insulin in clinically normal cats." American Journal of Veterinary Research 55, no. 1 (1994): 127–31. http://dx.doi.org/10.2460/ajvr.1994.55.01.127.

Full text

Abstract:

Summary The absorption kinetics and glycemic effects of 3 long-acting insulin preparations (protamine zinc beefpork insulin, ultralente beef-pork insulin, and ultralente human insulin) were evaluated in 9 healthy, adult, domestic shorthair cats (6 males, 3 females). A triple crossover study was performed, in which the serial serum concentrations of insulin and glucose were determined over a 24-hour period after SC administration of the 3 insulin preparations (dosage, 1.0 U/kg of body weight) at 3-week intervals. A control study was also performed in 4 of the cats by serially collecting samples

APA, Harvard, Vancouver, ISO, and other styles

19

Peterson, Gregory E. "Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir." Current Medical Research and Opinion 22, no. 12 (2006): 2613–19. http://dx.doi.org/10.1185/030079906x154178.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Danne, Thomas, and Jan Bolinder. "New Insulins and Insulin Therapy." Diabetes Technology & Therapeutics 15, S1 (2013): S—40—S—47. http://dx.doi.org/10.1089/dia.2013.1505.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Danne, Thomas, and Jan Bolinder. "New Insulins and Insulin Therapy." Diabetes Technology & Therapeutics 16, S1 (2014): S—34—S—43. http://dx.doi.org/10.1089/dia.2014.1505.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Bolinder, Jan, and Thomas Danne. "New Insulins and Insulin Therapy." Diabetes Technology & Therapeutics 17, S1 (2015): S—39—S—46. http://dx.doi.org/10.1089/dia.2015.1505.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Danne, T., and J. Bolinder. "New insulins and insulin therapy." International Journal of Clinical Practice 65 (February 2011): 26–30. http://dx.doi.org/10.1111/j.1742-1241.2010.02576.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Danne, Thomas, and Jan Bolinder. "New insulins and insulin therapy." International Journal of Clinical Practice 66 (February 2012): 30–34. http://dx.doi.org/10.1111/j.1742-1241.2011.02851.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Mao, Xuhua, Hucheng Chen, Junmin Tang, Liangliang Wang, and Tingting Shu. "Hepcidin links gluco-toxicity to pancreatic beta cell dysfunction by inhibiting Pdx-1 expression." Endocrine Connections 6, no. 3 (2017): 121–28. http://dx.doi.org/10.1530/ec-16-0115.

Full text

Abstract:

Objective Gluco-toxicity is a term used to convey the detrimental effect of hyperglycemia on β-cell function through impaired insulin synthesis. Although it is known that the expression and activity of several key insulin transcription regulators is inhibited, other molecular mechanisms that mediate gluco-toxicity are poorly defined. Our objective was to explore the role of hepcidin in β-cell gluco-toxicity. Design We first confirmed that high glucose levels inhibited hepcidin expression in the mouse insulinoma cell line, MIN6. The downregulation of hepcidin decreased Pdx-1 expression, which r

APA, Harvard, Vancouver, ISO, and other styles

26

Petrukhin, Aleksey. "Pump Insulin Therapy and Continuous Glycemic Monitoring." Spravočnik vrača obŝej praktiki (Journal of Family Medicine), no. 6 (June 1, 2020): 26–32. http://dx.doi.org/10.33920/med-10-2006-03.

Full text

Abstract:

Diabetes mellitus is a chronic disease, which is based on insufficient insulin production, which ultimately leads to the development of hyperglycemia. As a result of the continuous increase in blood sugar levels, many organs and systems suffer, and diabetes is one of the common causes of disability. After the discovery of the true nature of the disease, the main method of treatment is the administration of insulin. The dose and frequency of administration of this drug are selected individually and can be adjusted during treatment. The insulins used at the present stage are represented by ultra

APA, Harvard, Vancouver, ISO, and other styles

27

Dzhavakhishvili, T. Sh, T. I. Romantsova, and O. V. Roik. "Dinamika massy tela u bol'nykh sakharnymdiabetom 2 tipa v techenie pervogo godainsulinoterapii." Obesity and metabolism 7, no. 4 (2010): 13–19. http://dx.doi.org/10.14341/2071-8713-5082.

Full text

Abstract:

The aim of this study was to determine changes in weight and insulin requirements in insulin-treated type 2 diabetic patients with normal and elevated body mass index (BMI) during the first year after initiating the insulin therapy with insulin analogues or human insulins, respectively. Materials and methods: a total of 157 patients with insulin naive type 2 diabetes were included in the study. The patients were divided in two groups. First group consisted of subjects [mean age 57 (45 to 73), duration of diabetes of 10 years (4 to 16)] prescribed a long-acting basal (glargine, detemir), premix

APA, Harvard, Vancouver, ISO, and other styles

28

Sandow, Juergen, Wolfgang Landgraf, Reinhard Becker, and Gerhard Seipke. "Equivalent Recombinant Human Insulin Preparations and their Place in Therapy." European Endocrinology 11, no. 1 (2015): 10. http://dx.doi.org/10.17925/ee.2015.11.01.10.

Full text

Abstract:

Recombinant human insulin was one of the first products of biotechnology. It was developed in response to the need for a consistent and sufficient worldwide supply. Recombinant human insulin replaced the animal insulins and semisynthetic insulins obtained by modification of animal insulins. Bioequivalence studies were required for regulatory approval. Three reference products were independently established during these procedures: Humulin® (Eli Lilly and Co), Novolin® (NovoNordisk) and Insuman® (Sanofi). Numerous brand names have been used during the commercial development of recombinant human

APA, Harvard, Vancouver, ISO, and other styles

29

Rosenstock, Julio, Harpreet S. Bajaj, Ildiko Lingvay, and Simon R. Heller. "Clinical perspectives on the frequency of hypoglycemia in treat-to-target randomized controlled trials comparing basal insulin analogs in type 2 diabetes: a narrative review." BMJ Open Diabetes Research & Care 12, no. 3 (2024): e003930. http://dx.doi.org/10.1136/bmjdrc-2023-003930.

Full text

Abstract:

The objective of this review was to comprehensively present and summarize trends in reported rates of hypoglycemia with one or two times per day basal insulin analogs in individuals with type 2 diabetes to help address and contextualize the emerging theoretical concern of increased hypoglycemic risk with once-weekly basal insulins.Hypoglycemia data were extracted from treat-to-target randomized clinical trials conducted during 2000–2022. Published articles were identified on PubMed or within the US Food and Drug Administration submission documents. Overall, 57 articles were identified: 44 asse

APA, Harvard, Vancouver, ISO, and other styles

30

Diaz, J. L., and T. J. Wilkin. "Effect of iodination site on binding of radiolabeled ligand by insulin antibodies and insulin autoantibodies." Clinical Chemistry 34, no. 2 (1988): 356–59. http://dx.doi.org/10.1093/clinchem/34.2.356.

Full text

Abstract:

Abstract Four human insulins and four porcine insulins, each monoiodinated to the same specific activity at one of the four tyrosine residues (A14, A19, B16, B26) and purified by reversed-phase liquid chromatography, were tested in a radiobinding assay against a panel of insulin-antibody (IA)-positive sera from 10 insulin-treated diabetics and insulin-autoantibody-positive (IAA) sera from 10 nondiabetics. Of the 10 IAA-positive sera, five were fully cross reactive with both insulin species, and five were specific for human insulin. The rank order of binding of sera with the four ligands from e

APA, Harvard, Vancouver, ISO, and other styles

31

Xu, Juan, Shanshan Zhang, Guohui Zhang, Lihua Huang, and Qinghua Yi. "Research Progress on the Efficacy and Safety of Different Basal Insulins in the Treatment of Type 2 Diabetes Mellitus." Journal of Clinical and Nursing Research 8, no. 6 (2024): 21–25. http://dx.doi.org/10.26689/jcnr.v8i6.7670.

Full text

Abstract:

Objective: To evaluate the efficacy and safety of different basal insulins in the treatment of type 2 diabetes mellitus (T2DM). Methods: The current research progress on different basal insulins was evaluated, with efficacy indicators including fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c), and safety indicators focusing mainly on weight change and the incidence of hypoglycemia. Results: Several different basal insulins showed similar metabolic control effects in terms of fasting plasma glucose and glycated hemoglobin. However, the risk of hypoglycemia was lower with insulin gla

APA, Harvard, Vancouver, ISO, and other styles

32

Rasmussen, Jack T., and Heather J. Ipema. "Formulary Considerations for Insulins Approved Through the 505(b)(2) “Follow-on” Pathway." Annals of Pharmacotherapy 53, no. 2 (2018): 204–10. http://dx.doi.org/10.1177/1060028018795834.

Full text

Abstract:

Objective: To summarize formulary-relevant issues for follow-on insulins approved through the Food and Drug Administration (FDA) 505(b)(2) approval pathway (Basaglar and Admelog). Data Sources: A search of the MEDLINE database was performed for articles pertaining to clinical and formulary considerations for follow-on insulin products through July 2018. Study Selection and Data Extraction: All clinical trials used in the 505(b)(2) approval process for follow-on insulin glargine and insulin lispro products were included and summarized. Data Synthesis: Follow-on insulin glargine and insulin lisp

APA, Harvard, Vancouver, ISO, and other styles

33

Kumar, Sinha Ritesh, and Chandra Satish. "Insulin resistance." Asian Pacific Journal of Health Sciences, Supplimentary 2014 (2014): 71–78. http://dx.doi.org/10.21276/apjhs.2014.1.1s.15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Bansal, Naresh, Narendra Kotwal, Anuj Singhal, and Ashish Kumar. "Insulin: The Journey Continues." Journal of Marine Medical Society 26, no. 1 (2023): 3–8. http://dx.doi.org/10.4103/jmms.jmms_90_23.

Full text

Abstract:

Abstract In the history of medicine, the discovery of insulin marked a turning point. At first, the only form of insulin that could be administered to humans was this secretion from animal pancreas. Since its conception, technologies for purifying and altering insulin have been developed, although they are still a long way from simulating pancreatic-cells’ natural production. The precise structure of the insulin molecule had been uncovered by the late 1950s, and with the development of molecular biology and recombinant DNA techniques, it is now feasible to manipulate genes to produce recombina

APA, Harvard, Vancouver, ISO, and other styles

35

Andrade, Pedro, Luísa Barros, and Margarida Gonçalo. "Type 1 Ig-E mediated allergy to human insulin, insulin analogues and beta-lactam antibiotics." Anais Brasileiros de Dermatologia 87, no. 6 (2012): 917–19. http://dx.doi.org/10.1590/s0365-05962012000600018.

Full text

Abstract:

Insulin, a crucial therapeutic agent for diabetes mellitus, has been rarely associated with hypersensitivity events. We present a 69-year-old type-2 diabetic patient with urticariform lesions on the sites of subcutaneous injection of insulin. The patient denied any known allergies, except for an unspecific cutaneous reaction after intramuscular penicillin administration in childhood. Prick tests revealed positive reactions to all tested human insulins and insulin analogues. Serum IgE levels were above normal range and RAST tests were positive for human, bovine and porcine insulins, as well as

APA, Harvard, Vancouver, ISO, and other styles

36

Thomas, J. W., V. J. Virta, and L. J. Nell. "Heterogeneity and specificity of human anti-insulin antibodies determined by isoelectric focusing." Journal of Immunology 134, no. 2 (1985): 1048–52. http://dx.doi.org/10.4049/jimmunol.134.2.1048.

Full text

Abstract:

Abstract Anti-insulin antibodies are present in the majority of insulin treated diabetics, and in some cases these antibodies have been found to be highly specific for limited epitopes on the molecule. To determine how the human response differs from that seen in inbred animals, we have examined the heterogeneity and specificity of human anti-insulin antibodies by isoelectric focusing (IEF). In addition, we have used human insulin to examine the extent of autoreactivity in the serum of subjects treated with animal insulins. The majority of diabetic sera exhibited complex IEF spectra that were

APA, Harvard, Vancouver, ISO, and other styles

37

Duan, C., T. Noso, S. Moriyama, H. Kawauchi, and T. Hirano. "Eel insulin: isolation, characterization and stimulatory actions on [35S]sulphate and [3H]thymidine uptake in the branchial cartilage of the eel in vitro." Journal of Endocrinology 133, no. 2 (1992): 221–30. http://dx.doi.org/10.1677/joe.0.1330221.

Full text

Abstract:

ABSTRACT Our previous studies have shown that mammalian and salmon insulins stimulate sulphate uptake by cultured eel cartilage, suggesting the possible involvement of insulin in the regulation of cartilage matrix synthesis. In the present study, homologous eel insulin was isolated and characterized, and its effects on cartilage matrix synthesis and DNA synthesis were examined in vitro. Insulin was extracted from eel pancreas with acid–ethanol, and subsequently purified by isoelectric precipitation at pH 5·3, gel filtration on Sephadex G-50, and reversed-phase high-performance liquid chromatog

APA, Harvard, Vancouver, ISO, and other styles

38

Ndayishimye, Samuel *. Prudence A. Rodrigues. "HUMAN INSULIN AND INSULIN ANALOGUES IN MANAGEMENT OF DIABETES MELLITUS." Journal of Pharma Research 7, no. 10 (2018): 224–26. https://doi.org/10.5281/zenodo.1468476.

Full text

Abstract:

<em>ABSTRACT</em> <strong><em>T</em></strong><em>he aim of the study was to determine the outcomes of human insulin and insulin analogues in the management of diabetes mellitus. Since good glycemic control is needed for diabetic insulin analogues are having faster onset and shorter duration of action when compared to human insulin. Insulin analogues show improvements in clinical outcomes, medication adherence and patient satisfaction. When compared with human insulin, insulin analogues are having lesser episodes of hypoglycemia. Premixed insulin analogues show little benefits than Rapid and lo

APA, Harvard, Vancouver, ISO, and other styles

39

Bajaj, M., T. L. Blundell, R. Horuk, et al. "Coypu insulin. Primary structure, conformation and biological properties of a hystricomorph rodent insulin." Biochemical Journal 238, no. 2 (1986): 345–51. http://dx.doi.org/10.1042/bj2380345.

Full text

Abstract:

Insulin from a hystricomorph rodent, coypu (Myocaster coypus), was isolated and purified to near homogeneity. Like the other insulins that have been characterized in this Suborder of Rodentia, coypu insulin also exhibits a very low (3%) biological potency, relative to pig insulin, on lipogenesis in isolated rat fat-cells. The receptor-binding affinity is significantly higher (5-8%) in rat fat-cells, in rat liver plasma membranes and in pig liver cells, indicating that the efficacy of coypu insulin on receptors is about 2-fold lower than that of pig insulin. The primary structures of the oxidiz

APA, Harvard, Vancouver, ISO, and other styles

40

Skowronek, Rafał, Ewa Zielińska-Pająk, and Piotr Paleń. "Immunohistochemical detection of insulin at the injection site in a case of suspected murder with the suicide of the perpetrator." Archives of Forensic Medicine and Criminology 72, no. 3 (2023): 147–50. http://dx.doi.org/10.4467/16891716amsik.22.017.17395.

Full text

Abstract:

In medicolegal practice, rare cases involving suicidal, criminal, or accidental insulin overdose are both analytically and forensically challenging. The aim of this study is to present a model procedure in such cases, developed at the Department of Forensic Medicine and Toxicology of the Medical University of Silesia in Katowice, with particular emphasis on the possibility of additional confirmation of insulin intake by its immunohistochemical detection at the injection site. In the example case presented here, an immunohistochemical examination using FLEX Polyclonal Guinea Pig Anti-Insulin an

APA, Harvard, Vancouver, ISO, and other styles

41

Jayagopal, Vijay, Russell Drummond, and Dinesh Nagi. "Association of British Clinical Diabetologists (ABCD) position statement on the use of biosimilar insulin." British Journal of Diabetes 18, no. 4 (2018): 171–74. http://dx.doi.org/10.15277/bjd.2018.190.

Full text

Abstract:

Biosimilar insulins have the potential to offer the NHS a considerable cost saving. The acceptability and use of biosimilar insulin by clinicians and patients may, however, be limited by lack of experience, understanding and concerns about safety and tolerability. This article summarises information on the advantages and disadvantages of using biosimilar insulins and an overview of the published evidence in relation to efficacy, tolerability and safety of current and expected Biosimilar Insulins. The position of the ABCD on the use of Biosimilar Insulin is stated along with the key practical c

APA, Harvard, Vancouver, ISO, and other styles

42

Gotham, Dzintars, Melissa J. Barber, and Andrew Hill. "Production costs and potential prices for biosimilars of human insulin and insulin analogues." BMJ Global Health 3, no. 5 (2018): e000850. http://dx.doi.org/10.1136/bmjgh-2018-000850.

Full text

Abstract:

IntroductionHigh prices for insulin pose a barrier to treatment for people living with diabetes, with an estimated 50% of 100 million patients needing insulin lacking reliable access. As insulin analogues replace regular human insulin (RHI) globally, their relative prices will become increasingly important. Three originator companies control 96% of the global insulin market, and few biosimilar insulins are available. We estimated the price reductions that could be achieved if numerous biosimilar manufacturers entered the insulin market.MethodsData on the price of active pharmaceutical ingredie

APA, Harvard, Vancouver, ISO, and other styles

43

Dedov, I. I., and M. V. Shestakova. "On the centenary of the insulin discovery." Diabetes mellitus 24, no. 1 (2021): 11–16. http://dx.doi.org/10.14341/dm12733.

Full text

Abstract:

The discovery of insulin and the beginning of its use in 1921–1922 made a revolution in endocrinology and in medicine in general. This significant event gave millions of patients with diabetes not only the opportunity to live, but also the hope that their life with this disease would be full.The article examines the history of insulin discovery, as well as the evolution of several generations of insulin preparations and the advantages of each of the generations that have radically changed not only life expectancy, but also its quality.The first generation — insulins of animal origin and the so

APA, Harvard, Vancouver, ISO, and other styles

44

&NA;. "Insulin analogues show promise as short-acting insulins in insulin-dependent diabetes." Inpharma Weekly &NA;, no. 798 (1991): 17. http://dx.doi.org/10.2165/00128413-199107980-00045.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Taylor, M. Joan, Krishan P. Chauhan, and Tarsem S. Sahota. "Glucose lowering strategies with insulin." British Journal of Diabetes 19, no. 2 (2019): 124–30. http://dx.doi.org/10.15277/bjd.2019.228.

Full text

Abstract:

People with type 1 diabetes must use insulin and a large fraction of those with type 2 condition also do so. Many therefore struggle with the unpredictable balancing of insulin dose with calorie intake and utility. A healthy pancreas makes meticulous adjustment on a continuous basis that present therapeutic insulin administration cannot match. However, much progress has been made to make it simpler to inject both background and fast-acting boost insulins with a view to better mimicking normal pancreatic output. The present fast insulins are reviewed with accent on the primary amino acid struct

APA, Harvard, Vancouver, ISO, and other styles

46

Ferencz, Viktória, Beatrix Domján, László Gerő, Tímea Tänczer, and Gy Ádám Tabák. "A normoglykaemia elérésének korlátai inzulinkezelt 2-es típusú cukorbetegekben." Orvosi Hetilap 156, no. 36 (2015): 1443–50. http://dx.doi.org/10.1556/650.2015.30239.

Full text

Abstract:

Insulin therapy is the most effective treatment of diabetes. It is proven to prevent microvascular disease and likely to decrease the risk of cardiovascular complications. However, these benefits are associated with a 2-3 times increased risk of hypoglycaemia and a faster weight gain compared to other antidiabetic medications. In addition, one study found elevated all-cause mortality among patients on intensive therapy (requiring more frequent insulinisation). Insulin has growth factor properties that may translate to increased mitogenicity. These factors could prevent the medical team or the

APA, Harvard, Vancouver, ISO, and other styles

47

Ewen, Margaret, Huibert-Jan Joosse, David Beran, and Richard Laing. "Insulin prices, availability and affordability in 13 low-income and middle-income countries." BMJ Global Health 4, no. 3 (2019): e001410. http://dx.doi.org/10.1136/bmjgh-2019-001410.

Full text

Abstract:

IntroductionGlobally, one in two people needing insulin lack access. High prices and poor availability are thought to be key contributors to poor insulin access. However, few studies have assessed the availability, price and affordability of different insulin types in low-income and middle-income countries in a systematic way.MethodsIn 2016, 15 insulin price and availability surveys were undertaken (using an adaptation of the WHO/Health Action International medicine price and availability measurement methodology) in Brazil, China (Hubei and Shaanxi Provinces), Ethiopia, Ghana, India (Haryana a

APA, Harvard, Vancouver, ISO, and other styles

48

Andrianova, E. A. "The use of ultra-short acting insulin preparations for insulin pumps." Problems of Endocrinology 58, no. 3 (2012): 46–50. http://dx.doi.org/10.14341/probl201258346-50.

Full text

Abstract:

The data on the efficacy of using ultra-short acting insulin preparations in insulin pumps for children and adolescents presenting with diabetes mellitus. Insulin pump therapy in the patients of these age groups is finding an increasingly wider application as being more convenient for the users and leading to the improvement of glycemic control. One of the main advantages of modern insulin pump therapy is the possibility to maximally imitate the physiological profile of insulin secretion. The flexibility of both basal and bolus dosing regimens of insulin administration can be further increased

APA, Harvard, Vancouver, ISO, and other styles

49

&NA;. "Insulin/insulin aspart/insulin glargine." Reactions Weekly &NA;, no. 1338 (2011): 24. http://dx.doi.org/10.2165/00128415-201113380-00077.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Danne, Thomas, Lutz Heinemann, and Jan Bolinder. "New Insulins, Biosimilars, and Insulin Therapy." Diabetes Technology & Therapeutics 23, S2 (2021): S—46—S—68. http://dx.doi.org/10.1089/dia.2021.2504.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!